Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection. Post navigation Previous Previous post: Energy & Utilities Roundup: Market TalkNext Next post: Ex-Tory minister Crispin Blunt pleads guilty to possession of crystal meth Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Related News A Climate Fix That Could Cut Your Water Bill 0 Anatomy of a speech: how does a Republican leader say no to Trump? 0
